Mike Trower

Mike is a Founder and Chief Scientific Officer of NeRRe, who recognised and championed the belief that next generation neurokinin-1 receptor antagonists such as the company’s lead clinical asset orvepitant could present an exciting new approach to effectively treat neuronal hypersensitivity disorders with significant unmet need including chronic refractory cough. Mike was deeply involved in the acquisition of the Company’s neurokinin antagonist portfolio from GSK and the initial Series A fund raising to launch NeRRe in 2012.